Rate My Professor Daniela Salvemini

Salvemini’s research centers on molecular mechanisms driving neuropathic and chronic pain, including chemotherapy-induced neuropathy, neuroinflammatory processes in the periphery and central nervous system, peroxynitrite-mediated nitroxidative stress, the ceramide-to-sphingosine-1-phosphate pathway, and A3 adenosine receptor signaling in opioid-induced hyperalgesia and tolerance. She has authored over 250 peer-reviewed articles, with highly cited publications such as “Nitric oxide activates cyclooxygenase enzymes” (Proceedings of the National Academy of Sciences, 1993) and “Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury” (Pharmacological Reviews, 2001). Her contributions include key papers on peroxynitrite modulation in pain signaling (Journal of Neuroscience, 2012) and A3 adenosine receptor activation for chronic pain (FASEB Journal, 2012). Recognized with awards including the Novartis Prize in Pharmacology (1997), Premio Internazionale Maria Luisa de’ Medici (2010), Pharmacia-ASPET Award in Experimental Therapeutics, Outstanding Scientist Award from the Saint Louis Academy of Science, and Mitchell B. Max Award for Neuropathic Pain, she is a Fellow of the National Academy of Inventors, Saint Louis Academy of Science, and American Society for Pharmacology and Experimental Therapeutics. Salvemini founded BioIntervene Inc. and Vincion Inc. to advance non-opioid pain therapies into clinical trials, holds multiple U.S. patents, and maintains continuous funding from NIH, Department of Defense, and private sources. She co-founded the St. Louis Translational Pain Research Forum and serves on NIH study sections and the United States Association for the Study of Pain board.